You're using an outdated browser. This website will not display correctly and some features will not work.
Learn more about the browsers we support for a faster and safer online experience.

R.R.O. 1990, Reg. 935: GENERAL

under Drug Interchangeability and Dispensing Fee Act, R.S.O. 1990, c. P.23

Skip to content
Versions
current April 6, 2020 (e-Laws currency date)
January 1, 2020 April 5, 2020
December 13, 2019 December 31, 2019
October 1, 2016 December 12, 2019
September 23, 2016 September 30, 2016
October 1, 2015 September 22, 2016
September 18, 2015 September 30, 2015
April 1, 2013 September 17, 2015
January 23, 2013 March 31, 2013
April 1, 2012 January 22, 2013
April 1, 2011 March 31, 2012
July 1, 2010 March 31, 2011
June 7, 2010 June 30, 2010
October 16, 2008 June 6, 2010
July 12, 2007 October 15, 2008
July 4, 2007 July 11, 2007
April 1, 2007 July 3, 2007
December 14, 2006 March 31, 2007
October 1, 2006 December 13, 2006
September 28, 2006 September 30, 2006
September 6, 2006 September 27, 2006
August 24, 2006 September 5, 2006
August 22, 2006 August 23, 2006
August 10, 2006 August 21, 2006
July 17, 2006 August 9, 2006
July 5, 2006 July 16, 2006
June 15, 2006 July 4, 2006
June 14, 2006 June 14, 2006
May 31, 2006 June 13, 2006
May 19, 2006 May 30, 2006
May 5, 2006 May 18, 2006
April 19, 2006 May 4, 2006
April 4, 2006 April 18, 2006
March 21, 2006 April 3, 2006
March 3, 2006 March 20, 2006
March 1, 2006 March 2, 2006
February 15, 2006 February 28, 2006
January 24, 2006 February 14, 2006
January 12, 2006 January 23, 2006
January 10, 2006 January 11, 2006
December 9, 2005 January 9, 2006
December 6, 2005 December 8, 2005
November 22, 2005 December 5, 2005
November 8, 2005 November 21, 2005
October 25, 2005 November 7, 2005
October 6, 2005 October 24, 2005
September 27, 2005 October 5, 2005
September 22, 2005 September 26, 2005
September 16, 2005 September 21, 2005
September 1, 2005 September 15, 2005
August 30, 2005 August 31, 2005
August 19, 2005 August 29, 2005
August 5, 2005 August 18, 2005
July 14, 2005 August 4, 2005
June 29, 2005 July 13, 2005
June 13, 2005 June 28, 2005
May 30, 2005 June 12, 2005
May 25, 2005 May 29, 2005
May 2, 2005 May 24, 2005
April 28, 2005 May 1, 2005
March 31, 2005 April 27, 2005
March 23, 2005 March 30, 2005
February 24, 2005 March 22, 2005
February 22, 2005 February 23, 2005
February 16, 2005 February 21, 2005
February 3, 2005 February 15, 2005
January 25, 2005 February 2, 2005
January 21, 2005 January 24, 2005
December 21, 2004 January 20, 2005
December 9, 2004 December 20, 2004
November 16, 2004 December 8, 2004
November 10, 2004 November 15, 2004
November 4, 2004 November 9, 2004
October 14, 2004 November 3, 2004
October 8, 2004 October 13, 2004
October 6, 2004 October 7, 2004
September 14, 2004 October 5, 2004
September 3, 2004 September 13, 2004
August 11, 2004 September 2, 2004
August 4, 2004 August 10, 2004
July 20, 2004 August 3, 2004
June 28, 2004 July 19, 2004
April 6, 2004 June 27, 2004
March 12, 2004 April 5, 2004
September 4, 2003 March 11, 2004
82 more

Drug Interchangeability and Dispensing Fee Act
Loi sur l’interchangeabilité des médicaments et les honoraires de préparation

R.R.O. 1990, REGULATION 935

Amended to O. Reg. 458/06

GENERAL

Historical version for the period September 28, 2006 to September 30, 2006.

This Regulation is made in English only.

1. (1) In this Regulation,

“Formulary” means the Ministry of Health and Long-Term Care publication titled “Drug Benefit Formulary/Comparative Drug Index” (No. 39) dated September 27, 2005, and includes the following amendments to the publication:

1. Amendments dated January 12, 2006.

2. Amendments dated April 19, 2006.

3. Amendments dated June 15, 2006;

Note: On October 1, 2006, the definition of “formulary” is revoked. See: O. Reg. 458/06, ss. 1 (1), 7 (1).

“original product” means the original source of a drug product in a particular strength and dosage form that is or was designated as a listed drug product under Ontario Regulation 201/96 or that was listed as a drug product under Regulation 868 of the Revised Regulations of Ontario, 1990 (General) or the Parcost C.D.I. prescribed under Ontario Regulation 839/84 as it read on November 30, 1986;

Note: On October 1, 2006, the definition of “original product” is revoked and the following substituted:

“original product” means the original source of a drug product in a particular strength and dosage form that is or was designated on or after October 1, 2006 as a listed drug product by the executive officer or under Ontario Regulation 201/96 (General) under the Ontario Drug Benefit Act before October 1, 2006 or that was listed as a drug product under Regulation 868 of the Revised Regulations of Ontario, 1990 (General) or the Parcost C.D.I. prescribed under Ontario Regulation 839/84 as it read on November 30, 1986;

See: O. Reg. 458/06, ss. 1 (2), 7 (1).

Note: On April 1, 2007, the definition of “original product” is revoked and the following substituted:

“original product” means the original source of a drug product in a particular strength and dosage form;

See: O. Reg. 458/06, ss. 1 (3), 7 (2).

“production size lot” means the amount of finished product that is made from the minimum quantity of raw materials specified in a formula that can be processed using full sized production equipment into a dosage form that meets the specifications for the finished product.

R.R.O. 1990, Reg. 935, s. 1; O. Reg. 235/92, s. 1; O. Reg. 460/92, s. 1; O. Reg. 757/92, s. 1; O. Reg. 101/93, s. 1; O. Reg. 318/93, s. 1 (1); O. Reg. 453/93, s. 1; O. Reg. 524/93, s. 1; O. Reg. 526/93, s. 1; O. Reg. 735/93, s. 1; O. Reg. 49/94, s. 1 (1); O. Reg. 108/94, s. 1; O. Reg. 452/94, s. 1 (1); O. Reg. 615/94, s. 1; O. Reg. 755/94, s. 1 (1); O. Reg. 792/94, s. 1; O. Reg. 40/95, s. 1; O. Reg. 305/95, s. 1; O. Reg. 371/95, s. 1; O. Reg. 479/95, s. 1 (1); O. Reg. 177/96, s. 1; O. Reg. 337/96, s. 1; O. Reg. 376/96, s. 1; O. Reg. 509/96, s. 1 (1); O. Reg. 28/97 s. 1; O. Reg. 111/97, s. 1; O. Reg. 300/97, s. 1; O. Reg. 613/98, s. 1; O. Reg. 73/99, s. 1; O. Reg. 333/99, s. 1; O. Reg. 402/99, s. 1; O. Reg. 587/99, s. 1; O. Reg. 201/00, s. 1 (1); O. Reg. 367/00, s. 1; O. Reg. 583/00, s. 1; O. Reg. 15/01, s. 1; O. Reg. 173/01, s. 1 (1); O. Reg. 359/01, s. 1; O. Reg. 63/02, s. 1; O. Reg. 215/02, s. 1; O. Reg. 394/02, s. 1; O. Reg. 89/03, s. 1; O. Reg. 335/03, s. 1; O. Reg. 59/04, s. 1; O. Reg. 183/04, s. 1; O. Reg. 215/04, s. 1; O. Reg. 277/04, s. 1; O. Reg. 319/04, s. 1; O. Reg. 358/04, s. 1; O. Reg. 378/04, s. 1; O. Reg. 6/05, s. 1; O. Reg. 13/05, s. 1; O. Reg. 35/05, s. 1; O. Reg. 128/05, s. 1; O. Reg. 188/05, s. 1; O. Reg. 190/05, s. 1; O. Reg. 240/05, s. 1; O. Reg. 418/05, s. 1; O. Reg. 458/05, s. 1; O. Reg. 485/05, s. 1 (1); O. Reg. 488/05, s. 1; O. Reg. 500/05, s. 1 (1); O. Reg. 545/05, s. 1; O. Reg. 54/06, ss. 1 (1); O. Reg. 203/06, s. 1.

(1.1) Revoked: O. Reg. 54/06, s. 1 (2).

(1.2) For the purposes of this Regulation, items 17 and 18 of Part III of the Formulary shall be read as follows:

VORICONAZOLE

17

50mg Tab

   

11.8800

 

02256460

Vfend

PFI

11.8800

18

200mg Tab

   

47.5000

 

02256479

Vfend

PFI

47.5000

 

Reason for Use Code

Clinical Criteria

 

399

Outpatient continuation of treatment for documented invasive aspergillosis in patients who have demonstrated a clinical response to either oral or parenteral voriconazole. The first prescription must be written by a physician based at the hospital where the patient was hospitalized. Note: Limited to 3 months of reimbursement. LU Authorization Period: 1 year.

O. Reg. 644/05, s. 1.

Note: On October 1, 2006, subsection (1.2) is revoked. See: O. Reg. 458/06, ss. 1 (4), 7 (1).

(1.3) For the purposes of this Regulation, item 231 of Part III of the Formulary shall be read as follows:

231

2.5 mg Tab

   

4.9500

 

02231384

Femara (Letrozole)

NOV

4.9500

 

Reason for Use Code

Clinical Criteria

 

365

For the treatment of metastatic breast cancer in hormone receptor positive postmenopausal women. LU Authorization Period: Indefinite.

 

403

For the treatment of hormone receptor positive early breast cancer in postmenopausal women who have received 5 years of adjuvant tamoxifen therapy. LU Authorization Period: 5 Years.

O. Reg. 54/06, s. 1 (3).

Note: On October 1, 2006, subsection (1.3) is revoked. See: O. Reg. 458/06, ss. 1 (4), 7 (1).

(2) For the purposes of this Regulation, Items 1339, 1341, 1342, 1343, 1344, 1345, 1346, 1347, 1348, 1349, 1350, 1351, 1352, 1353, 1354, 1356, 1357, 1360 and 1361 of Part III of the Formulary are revoked. O. Reg. 485/05, s. 1 (3).

Note: On October 1, 2006, subsection (2) is revoked and the following substituted:

(2) For the purposes of subsection 1 (2) of the Act,

“therapeutic substitution” means the substitution of a drug that contains chemically different active ingredients that are considered to be therapeutically equivalent, without authorization from a person authorized to prescribe drugs within the scope of his or her practice of a health profession. O. Reg. 458/06, s. 1 (4).

See: O. Reg. 458/06, ss. 1 (4), 7 (1).

(3) For the purposes of this Regulation, Items 1330, 1331 and 1332 of Part III of the Formulary shall be read as follows:

1330

00030783

Depo-Testosterone 100mg/mL Oily Inj Sol-10mL Pk

UPJ

23.2100

1331

00029246

Delatestryl 1000mg/5mL Oily Inj Sol-5mL Pk

THE

22.8500

1332

00782327

Andriol 40mg Cap

ORG

0.9400

 

Reason for Use Code

Clinical Criteria

   
 

397

For male patients with confirmed low morning serum testosterone levels associated with documented, symptomatic hypothalamic, pituitary or testicular disease, or in HIV-infected patients.

   
   

Note: Older males with nonspecific symptoms of fatigue, malaise, depression who have a low normal random testosterone level do not satisfy these criteria.

LU authorization period: 1 year

   

O. Reg. 485/05, s. 1 (3).

Note: On October 1, 2006, subsection (3) is revoked. See: O. Reg. 458/06, ss. 1 (4), 7 (1).

(4) For the purposes of this Regulation, Items 1333, 1334, 1335, 1336, 1337, 1358 and 1359 of Part III of the Formulary shall be read as follows:

1333

02242878

Premplus 0.625mg/2.5mg Tab-28 Day Pk

WAY

7.0000

1334

02242879

Premplus 0.625mg/5mg Tab-28 Day Pk

WAY

7.0000

1335

02043394

Premarin 0.3mg Tab

WAY

0.1058

1336

00265470

C.E.S. 0.625mg Tab

ICN

0.0774

 

02043408

Premarin 0.625mg Tab

WAY

0.1215

1337

00265489

C.E.S. 1.25mg Tab

ICN

0.1293

 

02043424

Premarin 1.25mg Tab

WAY

0.2163

1358

02089769

Ogen 1.25 1.5mg Tab

UPJ

0.2804

1359

02089777

Ogen 2.5 3mg Tab

UPJ

0.4435

 

Reason for Use Code

Clinical Criteria

   
 

398

For short-term use in women who are experiencing symptoms of menopause.

   
   

Note: Recent evidence has demonstrated that use of hormone replacement therapy (HRT) increases the rate of coronary events, breast cancer, dementia, stroke, venous thromboembolism and referrals for abnormal vaginal bleeding. These risks should be discussed with patients and reviewed periodically.

LU authorization period: 1 year

   

O. Reg. 485/05, s. 1 (3).

Note: On October 1, 2006, subsection (4) is revoked. See: O. Reg. 458/06, ss. 1 (4), 7 (1).

(5) Revoked: O. Reg. 485/05, s. 1 (2).

(6) For the purposes of this Regulation, items 392, 393, 394, 395, 396, 398, 1158, 1285, 1286 and 1287 of Part III of the Formulary shall be read as follows:

392

2265273

Novo-Warfarin 1mg Tab

393

2265281

Novo-Warfarin 2mg Tab

394

2265303

Novo-Warfarin 2.5mg Tab

395

2265311

Novo-Warfarin 3mg Tab

396

2265338

Novo-Warfarin 4mg Tab

398

2265346

Novo-Warfarin 5mg Tab

1158

2246083

Apo-Ipravent 0.03% Nasal Spray

1285

2245456

Sodium Aurothiomalate 10mg/mL Inj Sol-1mL Pk

1286

2245457

Sodium Aurothiomalate 25mg/mL Inj Sol-1mL Pk

1287

2245458

Sodium Aurothiomalate 50mg/mL Inj Sol-1mL Pk

O. Reg. 500/05, s. 1 (2).

Note: On October 1, 2006, subsection (6) is revoked. See: O. Reg. 458/06, ss. 1 (4), 7 (1).

2. A product is designated as interchangeable with any other products it is indicated as interchangeable with in Part III of the Formulary. O. Reg. 235/92, s. 2.

Note: On October 1, 2006, section 2 is revoked and the following substituted:

2. (1) For the purposes of section 12.1 of the Act,

“professional allowance”, in the definition of “rebate”, means, subject to subsection (2), a benefit, in the form of currency, services or educational materials that are provided by a manufacturer to persons listed in subsection 12.1 (1) of the Act for the purposes of direct patient care as set out in paragraphs 1 to 8 of this subsection:

1. Continuing education programs that enhance the scientific knowledge or professional skills of pharmacists, if held in Ontario.

2. Continuing education programs for specialized pharmacy services or specialized certifications, if held in North America.

3. Clinic days provided by pharmacists to disseminate disease or drug-related information targeted to the general public including flu shot clinics, asthma clinics, diabetes management clinics, and similar clinics. For this purpose, a “clinic day” includes any additional staff to support the clinic day or the regular pharmacy business while the pharmacist is hosting a clinic day, during that day.

4. Education days provided by pharmacists that are targeted to the general public for health protection and promotion activities. Such education days must be held in the pharmacy, or a school, long-term care home, community centre, place of worship, shopping mall, or a place that is generally similar to any of these. For this purpose, an “education day” includes any additional staff to support the education day or the regular pharmacy business while the pharmacist is hosting an education day, during that day.

5. Compliance packaging that assists their patients with complicated medication regimes.

6. Disease management and prevention initiatives such as patient information material and services, blood pressure monitoring, blood glucose meter training, asthma management and smoking cessation, used in their pharmacy. For this purpose, “disease management and prevention initiatives” includes any additional staff required to support these initiatives or the regular pharmacy business while the pharmacist is hosting a disease management and prevention initiative, during the time it is being held.

7. Private counselling areas within their pharmacy.

8. Hospital in-patient or long-term care home resident clinical pharmacy services, such as medication reconciliation initiatives or other hospital or long-term care home-identified clinical pharmacy priorities. For this purpose, “clinical pharmacy services” includes the costs of any additional staff required to support these services or the regular pharmacy business while the pharmacist is hosting a clinical pharmacy service, during the time it is being held. O. Reg. 458/06, s. 2.

(2) A benefit is not a professional allowance if the contents of the Code of Conduct established under subsection 11.5 (15) of the Ontario Drug Benefit Act, and as set out in Schedule 1, are not complied with. O. Reg. 458/06, s. 2.

See: O. Reg. 458/06, ss. 2, 7 (1).

3. A product is designated as interchangeable with any other products it is indicated as interchangeable with in the following amendments to Part III of the Formulary:

1. Amendments dated September 30, 2005.

2. Amendments dated October 31, 2005.

3. Amendments dated November 30, 2005.

4. Amendments dated December 30, 2005.

5. Amendments dated February 28, 2006.

6. Amendments dated April 4, 2006.

7. Amendments dated April 28, 2006.

8. Amendments dated May 31, 2006.

9. Amendments dated June 30, 2006.

10. Amendments dated July 31, 2006.

11. Amendments dated August 31, 2006. O. Reg. 545/05, s. 2; O. Reg. 595/05, s. 1; O. Reg. 5/06, s. 1; O. Reg. 40/06, s. 1; O. Reg. 79/06, s. 1; O. Reg. 185/06, s. 1; O. Reg. 240/06, s. 1; O. Reg. 354/06, s. 1; O. Reg. 371/06, s. 1; O. Reg. 396/06, s. 1.

Note: On October 1, 2006, section 3 is revoked. See: O. Reg. 458/06, ss. 2, 7 (1).

4. Revoked: O. Reg. 204/96, s. 1.

5. A person may charge more than the person’s usual and customary dispensing fee for a product that is supplied pursuant to a prescription if the person explains why a fee in excess of the usual and customary fee is being charged prior to the dispensing of the prescription and the charging of the additional fee is not an act of professional misconduct under section 1 of Ontario Regulation 681/93 made under the Pharmacy Act, 1991. R.R.O. 1990, Reg. 935, s. 5; O. Reg. 377/94, s. 1.

6. (1) It is a condition for each strength and dosage form of a drug product to be designated as interchangeable with other products that the manufacturer of the drug product submit to the Minister,

Note: On October 1, 2006, subsection (1) is amended by striking out “Minister” in the portion before clause (a) and substituting “executive officer”. See: O. Reg. 458/06, ss. 3 (1), 7 (1).

(a) evidence that Health Canada has approved the product for sale in Canada, a copy of the product’s drug notification form issued by Health Canada and, subject to subsection (2), a copy of the product monograph approved by Health Canada;

(b) a letter authorizing the Minister to gain access to all information with respect to the product in the possession of Health Canada, the government of any province or territory in Canada or the Canadian Coordinating Office for Health Technology Assessment and authorizing the Minister to disclose any information with respect to the product in the possession of the Ministry to Health Canada, the government of a province or territory in Canada or the Canadian Coordinating Office for Health Technology Assessment;

Note: On October 1, 2006, clause (b) is revoked and the following substituted:

(b) a letter authorizing the executive officer to gain access to all information with respect to the product in the possession of Health Canada, the Patented Medicine Prices Review Board established under section 91 of the Patent Act (Canada), the government of any province or territory in Canada or the Canadian Agency for Drugs and Technologies in Health and authorizing the executive officer to disclose any information with respect to the product in the possession of the Ministry to Health Canada, the Patented Medicine Prices Review Board, the government of a province or territory in Canada or the Canadian Agency for Drugs and Technologies in Health;

See: O. Reg. 458/06, ss. 3 (2), 7 (1).

(c) documentation disclosing the product’s master formulation;

(d) the proposed drug benefit price of the product;

Note: On April 1, 2007, clause (d) is revoked and the following substituted:

(d) the proposed drug benefit price of the product, where it is proposed that the product be designated as a listed drug product under the Ontario Drug Benefit Act, and a proposed manufacturer’s list price where it is not proposed that the product be so designated;

See: O. Reg. 458/06, ss. 3 (3), 7 (2).

(d.1) Revoked: O. Reg. 496/00, s. 1 (4).

(e) evidence that the manufacturer is able to supply the product at the proposed drug benefit price in a quantity sufficient to meet the anticipated demand for the product;

Note: On April 1, 2007, clause (e) is revoked and the following substituted:

(e) evidence that the manufacturer is able to supply the product at the proposed drug benefit price in a quantity sufficient to meet the anticipated demand for the product where it is proposed that the product be designated as a listed drug product under the Ontario Drug Benefit Act;

See: O. Reg. 458/06, ss. 3 (3), 7 (2).

(f) Revoked: O. Reg. 28/97, s. 2 (2).

(g) Revoked: O. Reg. 496/00, s. 1 (5).

(h) comparative bioavailability studies on humans, comparative clinical studies on humans, or both, or other in vivo studies that will show the interchangeability of the product with the original product.

(i) Revoked: O. Reg. 496/00, s. 1 (6).

O. Reg. 18/96, s. 1; O. Reg. 204/96, s. 2; O. Reg. 28/97, s. 2 (1, 2); O. Reg. 496/00, s. 1 (1-6); O. Reg. 337/03, s. 1 (1); O. Reg. 644/05, s. 2.

(2) If Health Canada has not approved a product monograph for a drug product, the manufacturer of the product may, instead of submitting a copy of the product monograph as required under clause (1) (a), submit to the Minister the following information:

Note: On October 1, 2006, subsection (2) is amended by striking out “Minister” in the portion before paragraph 1 and substituting “executive officer”. See: O. Reg. 458/06, ss. 3 (4), 7 (1).

1. Pharmaceutical information.

2. Information with respect to the product’s clinical pharmacology.

3. Information as to the product’s indications and clinical use.

4. A list of any contra-indications, warnings or precautions in the use of the product and of possible adverse reactions to its use.

5. A list of symptoms of an overdose of the product and information as to the treatment of an overdose.

6. Information with respect to the dosage and administration of the product.

7. Information regarding the availability of dosage forms for each strength of the product marketed in Canada. O. Reg. 18/96, s. 1; O. Reg. 496/00, s. 1 (7).

(3) Clauses (1) (c) and (h) do not apply to the manufacturer of a drug product if the dosage form, strength, formula and manufacturing process of the product and the testing standards for both the raw materials of the product and the finished product are identical to those of the product with which it seeks to be designated as interchangeable. O. Reg. 18/96, s. 1; O. Reg. 496/00, s. 1 (8).

(4) A manufacturer may satisfy the condition set out in clause (1) (h) for a strength of a drug product by submitting the evidence referred to in clause (1) (h) for another strength of the same dosage form of the drug product if that information is sufficient for the purposes of evaluating the interchangeability of both the strengths of the dosage form of the product. O. Reg. 18/96, s. 1.

(5) Clause (1) (h) does not apply with respect to a drug product that is pharmaceutically equivalent to the original product, demonstrates the same physicochemical properties of the original product, is the same dosage form, packaging format and volume as the original product and is one of the following:

1. A parenteral aqueous solution, or a powder for reconstitution into an aqueous solution, that may be administered in an intravenous, intramuscular, subcutaneous or intrathecal fashion and that is in the same solvent and in the same concentration as the original product.

2. An oral solution, elixir, syrup or other similar solubilized form in the same concentration as the original product and which contains no ingredient that will affect the bioavailability of the active ingredient.

3. An ophthalmic, otic, nasal, rectal, vaginal or inhaled solution that is topical and aqueous. O. Reg. 18/96, s. 1; O. Reg. 496/00, s. 1 (9).

(5.1) For the purposes of subsection (5), if a drug product has been designated by Health Canada as equivalent to the original product or to another listed interchangeable product with which it would be designated as interchangeable, the drug product shall be deemed to be pharmaceutically equivalent to the original product and to demonstrate the same physicochemical properties of the original product. O. Reg. 485/05, s. 2 (1).

(6) Clause (1) (c) does not apply with respect to a product that has been designated by Health Canada as equivalent to the original product or to another listed interchangeable product with which it would be designated as interchangeable unless the product is described in subsection (5). O. Reg. 485/05, s. 2 (2).

(7) Clause (1) (h) does not apply to a product that is a solid oral dosage form for systemic effect and that has been designated by Health Canada as equivalent to the original product or to another listed interchangeable product with which it would be designated as interchangeable. O. Reg. 485/05, s. 2 (2).

Note: On October 1, 2006, section 6 is amended by adding the following subsection:

(8) Anything submitted to the Minister under this section before October 1, 2006 shall be deemed to have been submitted to the executive officer, and any authorization given to the Minister shall be deemed to have been given to the executive officer. O. Reg. 458/06, s. 3 (5).

See: O. Reg. 458/06, ss. 3 (5), 7 (1).

7. (1) This section sets out additional conditions to be met in order for a strength and dosage form of a product to be designated as interchangeable. O. Reg. 299/95, s. 1.

Note: On October 1, 2006, subsection (1) is amended by adding “where it is proposed that the product be designated as a listed drug product under the Ontario Drug Benefit Act” at the end. See: O. Reg. 458/06, ss. 4 (1), 7 (1).

(2) A strength and dosage form of a product shall not be designated as interchangeable with other products unless it meets the following conditions:

1. If the original product is a listed product and there are no other interchangeable products already designated, the drug benefit price of the product proposed to the Minister under clause 6 (1) (d) must be less than or equal to 70 per cent of the drug benefit price, as set out in Part III of the Formulary, of the product with which it would be interchangeable.

2. If the original product is a listed product and there are other interchangeable products already designated, the drug benefit price of the product proposed to the Minister under clause 6 (1) (d) must be,

i. if the original product was listed as a listed drug product on or before March 31, 1994, less than or equal to the greater of the following amounts,

A. 63 per cent of the drug benefit price of the original product, as set out in the Formulary at the time the proposal is made to the Minister under clause 6 (1) (d), or

B. 63 per cent of the best available price of the original drug product, as set out in the Formulary on March 31, 1994, and

ii. if the original product was listed as a listed drug product after March 31, 1994, less than or equal to the greater of the following amounts:

A. 63 per cent of the best available price or drug benefit price, as the case may be, of the original product, as set out in the Formulary at the time the original product was listed, or

B. 63 per cent of the drug benefit price of the original product at the time the proposal is made to the Minister under clause 6 (1) (d),

but in no event shall the drug benefit price of the proposed product be greater than the highest drug benefit price among the drug benefit prices set out in the Formulary for the products with which the proposed product would be interchangeable.

3. If the product is an original product that was but is no longer a listed drug product under Ontario Regulation 201/96 and if there are no other interchangeable products already designated, the drug benefit price of the product proposed to the Minister under clause 6 (1) (d) must be,

i. less than or equal to 70 per cent of the drug benefit price of the original product that was set out in the Formulary immediately before its removal, or

ii. if the original product was removed from the Formulary as a listed drug product before May 27, 1996, less than or equal to 70 per cent of the best available price that was set out in the Formulary immediately before the removal of the original product.

4. If the product is an original product that was but is no longer a listed drug product under Ontario Regulation 201/96 and if there are other interchangeable products already designated, the drug benefit price of the product proposed to the Minister under clause 6 (1) (d) must be,

i. less than or equal to 63 per cent of the drug benefit price of the original product that was set out in the Formulary immediately before its removal, or

ii. if the original product was removed from the Formulary as a listed drug product before May 27, 1996, less than or equal to 63 per cent of the best available price that was set out in the Formulary immediately before the removal of the original product. O. Reg. 220/98, s. 1; O. Reg. 593/98, s. 1; O. Reg. 496/00, s. 2.

Note: On October 1, 2006, subsection (2) is revoked and the following substituted:

(2) A strength and dosage form of a product shall not be designated as interchangeable with other products unless it meets the following conditions:

1. If the original product is a listed product the drug benefit price proposed to the executive officer under clause 6 (1) (d) must be less than or equal to 50 per cent of the drug benefit price, as set out in the Formulary, of the product with which it would be interchangeable.

2. Subject to paragraph 3, if the original product was but is no longer a listed drug product, the drug benefit price of the product proposed to the executive officer under clause 6 (1) (d) must be less than or equal to 50 per cent of the drug benefit price of the original product that was set out in the Formulary immediately before its removal.

3. If the original product was removed from the Formulary as a listed drug product before May 27, 1996, the drug benefit price of the product proposed to the executive officer under clause 6 (1) (d) must be less than or equal to 50 per cent of the best available price that was set out in the Formulary immediately before the removal of the original product.

4. In addition to the applicable conditions under paragraphs 1, 2 and 3, where the product is to be designated as a listed product under the Ontario Drug Benefit Act, and if required by the executive officer, the manufacturer of the product shall enter into an agreement with the executive officer that specifies any volume discount or other amount that may be payable by the manufacturer to the Minister of Finance, and shall agree that the executive officer may make public the following information, and that information only, with respect to the agreement:

i. The name of the manufacturer.

ii. The subject-matter of the agreement.

iii. The fact of entering into or terminating the agreement. O. Reg. 458/06, s. 4 (2).

See: O. Reg. 458/06, ss. 4 (2), 7 (1).

8. The following conditions must be met in order for a drug product that has been designated as interchangeable to continue to be designated as interchangeable:

1. The manufacturer of the product shall give the Minister notice of any change made to the product, including a formulation change, and of any change in the ownership of the manufacturer.

Note: On October 1, 2006, paragraph 1 is amended by striking out “Minister” and substituting “executive officer”. See: O. Reg. 458/06, ss. 5 (1), 7 (1).

2. The product must be authorized for sale under the Food and Drugs Act (Canada).

3. The manufacturer of the product must continue to be able to supply the product at the drug benefit price in a quantity that is sufficient to meet the demand for the product. O. Reg. 28/97, s. 3.

Note: On April 1, 2007, paragraph 3 is amended by adding “where the product is designated as a listed drug product under the Ontario Drug Benefit Act” at the end. See: O. Reg. 458/06, ss. 5 (2), 7 (2).

Note: On October 1, 2006, section 8 is amended by adding the following paragraphs:

4. Subject to paragraph 5, if the product is a listed drug product under the Ontario Drug Benefit Act, the drug benefit price of the product may not be more than the price that could be proposed to the executive officer under subsection 7 (2).

5. Paragraph 4 does not apply to a product that is designated as interchangeable with an original product where the original product has the same drug benefit price on the Formulary as the interchangeable product, or has no drug benefit price on the Formulary but in no case may the interchangeable product be priced higher than the original product.

6. Where a product is designated as a listed drug product under the Ontario Drug Benefit Act, and if required by the executive officer, the manufacturer of the product shall enter into and remain a party to an agreement with the executive officer that specifies any volume discount or other amount that may be payable by the manufacturer to the Minister of Finance, and shall agree that the executive officer may make public the following information, and that information only, with respect to the agreement:

i. The name of the manufacturer.

ii. The subject-matter of the agreement.

iii. The fact of entering into or terminating the agreement.

See: O. Reg. 458/06, ss. 5 (3), 7 (1).

Note: On April 1, 2007, section 8 is amended by adding the following paragraph:

7. If the drug product has not been designated as a listed drug product under the Ontario Drug Benefit Act, the manufacturer of the product shall give the executive officer notice of every change in the manufacturer’s list price for the drug product.

See: O. Reg. 458/06, ss. 5 (4), 7 (2).

Note: On October 1, 2006, section 8 is amended by adding the following subsection:

(2) For greater certainty, the conditions set out in subsection (1) apply whether the designation of the product as an interchangeable product took place before, on or after October 1, 2006. O. Reg. 458/06, s. 5 (5).

See: O. Reg. 458/06, ss. 5 (5), 7 (1).

Note: On October 1, 2006, the Regulation is amended by adding the following Schedule:

SCHEDULE 1
CODE OF CONDUCT

The Code of Conduct is intended to establish system-wide guidance governing the use of professional allowances to be paid by manufacturers to operators of pharmacies, or companies that own, operate or franchise pharmacies, or to their directors, officers, employees or agents.

Where the term “representative” is used in this Code of Conduct, it means an officer, director, employee, or agent.

Fundamental Principles

1. Payments from manufacturers to operators of pharmacies, or companies that own, operate or franchise pharmacies, including their directors, officers, employees or agents, in the form of a professional allowance must be used only for any or all of the activities set out in the definition of “professional allowance” in subsection 2 (1) of the regulation.

2. All persons involved in the drug distribution system must operate transparently. To act transparently, manufacturers, operators of pharmacies, or companies that own, operate or franchise pharmacies, including their directors, officers, employees or agents must make the executive officer and other stakeholders knowledgeable of, and fully understand, the flow of funds in the drug products supply chain. This includes recording and reporting all such payments as required by the executive officer, and being subject to audit by the Ministry or a third party.

3. All suppliers of drug products as well as operators of pharmacies, or companies that own, operate or franchise pharmacies, including their directors, officers, employees or agents, must commit to abide by this Code of Conduct. Any breach of the Code will be subject to enforcement as set out in the Ontario Drug Benefit Act and the Drug Interchangeability and Dispensing Fee Act.

Use of Professional Allowances

Operators of pharmacies or companies that own, operate or franchise pharmacies may use professional allowances. Programs and information contained in educational materials must be full, factual and without intent to mislead.

Professional allowances may never be used for:

1. Advertising or promotional materials, such as store flyers, except in association with clinic days or education days mentioned in paragraphs 3 and 4 of the definition of “professional allowance” in subsection 2 (1) of the regulation.

2. Entertainment, social and sporting events.

3. Meals and travel not directly associated with a program referred to in paragraphs 1 to 4 of the definition of “professional allowance” in subsection 2 (1) of the regulation.

4. Convention displays.

5. Personal gifts provided to operators of pharmacies, or companies that own, operate or franchise pharmacies, including their directors, officers, employees or agents.

6. Staff wages and benefits, except as provided for in paragraphs 3 and 4 of the definition of “professional allowance” in subsection 2 (1) of the regulation.

7. Packaging costs and delivery services in respect of a prescription and dispensing fees.

8. Taxes.

9. Inventory costs.

10. Fees or penalties for inventory adjustments.

11. Purchases of sales and prescription-related data.

12. Fees for listing products in inventory.

13. Renovations, leasehold improvements and similar matters.

14. Store fixtures.

15. Real estate purchases or sales, encumbrances, leases or rent.

Professional allowances are to be calculated based on the following criteria:

1. Reasonable costs to provide direct patient care as set out in paragraphs 1 to 8 of the definition of “professional allowance” in subsection 2 (1) of the regulation.

2. Reasonable frequency of providing direct patient care as set out in paragraphs 1 to 8 of the definition of “professional allowance” in subsection 2 (1) of the regulation.

3. A reasonable number of patients per pharmacy.

Manufacturers’ Representatives

Manufacturers’ representatives shall conduct business ethically and in a manner that is in the best interest of patients.

Any information provided by manufacturers’ representatives, whether written or oral, must be full, factual and without misrepresentation.

Manufacturers shall be held responsible for the behaviour of their representatives.

Pharmacy Representatives

Pharmacy representatives shall conduct business ethically and in a manner that is in the best interest of their patients.

Pharmacies must not make procurement and purchasing decisions based solely on the provision of professional allowances.

Reporting

Manufacturers will report to the executive officer the amount of professional allowance paid to each operator of a pharmacy, or company that owns, operates or franchises pharmacies, including their directors, officers, employees or agents, in as much detail as is required by the executive officer and at times required by the executive officer. The report must be signed by two officers of the manufacturer or by the manufacturer’s auditors, as may be required by the executive officer.

Operators of pharmacies, or companies that own, operate or franchise pharmacies will report to the executive officer the amount of professional allowance received from each manufacturer in as much detail as is required by the executive officer and at times required by the executive officer. The report must be signed by two officers of the operator of the pharmacy, or company that owns, operates or franchises pharmacies, or by their auditors, as may be required by the executive officer.

O. Reg. 458/06, s. 6.

See: O. Reg. 458/06, ss. 6, 7 (1).